Production of therapeutic proteins in genetically modified mammalian cells

Patent metadata

Field	Value
Publication number	US-10030063-B2
Application number	US-201314651694-A
Country	US
Kind code	B2
Filing date	Dec 16, 2013
Priority date	Dec 18, 2012
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

The invention relates to methods for the production of therapeutic proteins in mammalian cells. In one embodiment, the method comprises producing a therapeutic protein such as IGF-1 in a mammalian cell endogenously expressing a cognate receptor of said recombinant therapeutic protein and wherein binding of said therapeutic protein to said cognate receptor results in a low titer of the therapeutic protein, the method comprising with a mammalian cell being deficient in the expression of the cognate receptor of said therapeutic protein and being transformed with an expression vector comprising a nucleic acid molecule encoding the therapeutic protein: a. Cultivating said cell under conditions allowing the expression of the therapeutic protein; and b. Harvesting the therapeutic protein from the mammalian cell cultivated in step a, wherein said mammalian cell produces at least 1.5 fold more therapeutic protein than a cell in which the expression of the cognate receptor has not been so modified.

First claim

The invention claimed is:

1. A method of producing a protein in a mammalian cell, wherein the cell has been modified to be deficient in expression of a cognate receptor of the protein and has been transformed with a nucleic acid encoding the protein, the method comprising the steps of:
(a) Cultivating the cell under conditions allowing the expression of the protein; and
(b) Harvesting the protein from the cell cultivated in step (a),

wherein the cell produces at least 1.5-fold more protein than a cell in which the expression of the receptor has not been modified, wherein the protein is Insulin like growth factor 1 (IGF-1) protein or a variant thereof and the receptor is IGF-1 receptor (IGF-1R).

2. The method of claim 1 , wherein the deficiency in the expression of the receptor in the cell has been achieved by applying RNA interference or targeted genetic recombination.

3. The method of claim 2 , wherein the deficiency in the expression of the receptor in the cell has been achieved by applying RNA interference, the method comprising the steps of:
(c) introducing into the cell a double-stranded ribonucleic acid (dsRNA), wherein the dsRNA comprises a sense and an antisense strand, and wherein the sense strand comprises a first sequence, and the antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of the mRNA encoding the receptor, and wherein the region of complementarity is less than 30 nucleotides in length and wherein introduction of the dsRNA into the cell can inhibit expression of the gene encoding the receptor by at least 10%; and
(d) maintaining the cell produced in step (c) for a time sufficient to obtain degradation of the mRNA transcript of the gene encoding the receptor, thereby inhibiting expression of the receptor gene in the cell,
wherein the steps (c) and (d) are both performed before the steps (a) and (b).

4. The method of claim 2 , wherein the RNA interference is achieved using a shRNA, the method comprising the steps of:
(c) introducing into the cell a shRNA which is substantially complementary to at least a part of the mRNA encoding the receptor, and wherein introduction of the shRNA into the cell can inhibit expression of the receptor gene by at least 10%; and
(d) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the receptor gene,
wherein the steps (c) and (d) are both performed before the steps (a) and (b).

5. The method of claim 1 , wherein the cell which has been modified to be deficient in expression of IGF-1R is a CHO, COS, Vero, Hela, BHK, HEK, NS0, C127, hybridoma, PerC6, CAP, or Sp-2/0 cell.

6. The method of claim 5 , wherein the cell is a CHO-K1 derivative cell, a CHO-DUXB11 derivative cell, or a CHO-DG44 cell.

7. The method of claim 6 , wherein the cell has been modified using a shRNA in RNA interference, and wherein the sequence of the shRNA is selected from the group consisting of SEQ ID NO: 5, 6, 7, 8, 9 and 10.

8. The method of claim 3 , wherein the cognate receptor is IGF-1R of SEQ ID NO: 44, and the sequence of a strand of the dsRNA is SEQ ID NO: 1 or 3.

9. The method of claim 1 , wherein the deficiency in the expression of the IGF-1R has been achieved by the use of a zinc finger nuclease.

10. The method of claim 1 , wherein the growth factor is the human Insulin like growth factor 1 (IGF-1) protein of SEQ ID NO: 16 or a variant thereof.

11. The method of claim 1 , further comprising the steps of
c. Making the cell deficient in the expression of Insulin growth factor 1 receptor;
d. Transforming the cell with an expression vector comprising a nucleic acid encoding an IGF-1 or a variant thereof;
e. Selecting cell of step (d) being transformed;
wherein steps (c) and (d) can be performed in either order, and wherein steps (c), (d) and (e) are performed before steps (a) and (b).

12. The method of claim 1 , wherein the protein is produced at an industrial manufacturing scale.

13. The method of claim 1 , wherein the growth factor is a human insulin like growth factor 1 (IGF-1) protein variant selected from the group consisting of SEQ ID NO: 23, 24, 25, 26, 27, 28 and 29.

Assignees

• Fornaro Mara
• Glass David Jonathan
• Jostock Thomas
• Laux Holger
• Romand Sandrine
• Novartis Ag

Inventors

• Fornaro Mara
• Glass David Jonathan
• Jostock Thomas
• Laux Holger
• Romand Sandrine

Classifications

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• C07K14/65 Primary

  Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 · CPC title

• C12P21/02

  having a known sequence of two or more amino acids, e.g. glutathione · CPC title

• C12N2310/531

  Stem-loop; Hairpin · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title